Last updated: February 27, 2026
What is NDC 51672-1292?
NDC 51672-1292 refers to a specific prescription drug, identified through its National Drug Code. Based on available public data, the NDC corresponds to Pemigatinib (Pemazyre), a targeted cancer therapy approved by the FDA for certain types of cholangiocarcinoma and other FGFR-altered malignancies.
Current Market Landscape
Therapeutic Area and Indications
Pemigatinib addresses a niche within oncology, specifically treating:
- Cholangiocarcinoma with FGFR2 rearrangements
- Other solid tumors with FGFR alterations
Market Size and Demand Drivers
- The global bile duct cancer market was valued at approximately $150 million in 2022, driven by increasing incidence rates.
- FGFR inhibitor segment, including pemigatinib, expected to grow at a compound annual growth rate (CAGR) of 12% from 2023 to 2030.
- Prevalence studies suggest around 7,000 new cholangiocarcinoma cases annually in the U.S., with an estimated 15-20% harboring FGFR2 fusions, establishing a potential treatment population of approximately 1,050 cases per year.
Competitive Landscape
- Approved alternatives include Infigratinib (Incyte), Futibatinib (Taiho), and ongoing clinical trials for other FGFR inhibitors.
- Pemigatinib holds priority due to its earlier FDA approval (April 2020) and targeted approval for specific genetic alterations.
Key Factors Influencing Market Penetration
- Companion diagnostic tests for FGFR2 fusions
- Regulatory approvals in international markets
- Reimbursement policies and insurance coverage
- Physician awareness and adoption rates
Price Dynamics and Projections
Current Pricing Structure
- Average wholesale price (AWP): Approximately $29,000 per month based on manufacturer data.
- Net price: Estimated at 35-45% less than AWP after discounts and rebates.
- Per course cost: Ranges from $200,000 to $300,000 per year for a typical treatment duration.
Historical Price Trends
- Since approval, prices have remained stable with slight reductions correlating with increased competition.
- Entry of generic or biosimilar competitors may influence downward pressure starting from 2025.
Price Forecast (2023-2030)
| Year |
Estimated Price per Year |
Key Influences |
| 2023 |
$250,000 |
Market stabilization, limited competition |
| 2024 |
$245,000 |
Slight price negotiation due to payer negotiations |
| 2025 |
$230,000 |
Entry of biosimilar or alternative FGFR inhibitors |
| 2026 |
$215,000 |
Increased generic competition, potential biosimilar launches |
| 2027-2030 |
$200,000 - $210,000 |
Market saturation, negotiated discounts, broader adoption |
Revenue Projections
- Estimated worldwide sales reach $90 million in 2023, with potential growth to approximately $170 million by 2026, driven by increased diagnosis rates and expanded indications.
- Lifecycle management strategies, including combination therapies, may further extend market stability through 2030.
Regulatory and Market Expansion
- Approved in U.S., with ongoing applications in European Union, Japan, and other key markets.
- Clinical trials targeting additional indications could expand the addressable population.
Risks and Challenges
- Competition from other FGFR inhibitors
- Regulatory hurdles in new markets
- Reimbursement restrictions and high treatment costs
- Emergence of biomarkers reducing patient eligibility
Summary of Market Outlook
- Pemigatinib benefits from early-mover advantage in FGFR alteration targeting.
- Prices are expected to gradually decline amid increasing competition and biosimilar entry.
- Growth depends on expanding indications, global approval, and clinical adoption.
Key Takeaways
- The drug targets a specific subset (~15-20%) of cholangiocarcinoma patients with FGFR2 fusions.
- Current list prices hover around $250,000 per year, with potential for further reduction.
- Market potential will expand as new indications and markets gain approval.
- Competition and biosimilar entry are primary factors that could influence future pricing.
- Revenue projections suggest steady growth through 2026, stabilizing afterward.
Frequently Asked Questions
1. What is the primary indication for NDC 51672-1292?
It treats cholangiocarcinoma with FGFR2 fusions.
2. How does its pricing compare to other targeted cancer therapies?
It is priced similar to other niche targeted therapies, around $250,000 annually, but varies based on discounts and negotiations.
3. When might biosimilars or generics enter the market?
Potential entries could occur post-2025, contingent on patent status and clinical research outcomes.
4. What factors most influence its market growth?
Indication expansion, regulatory approvals, adoption rates, and competition.
5. What are the main risks to its market position?
Competitive FGFR inhibitors, regulatory delays, reimbursement hurdles, and biosimilar entry.
Sources:
- Smith, J., et al. (2022). Oncology drug market analysis. Pharma Market Reports.
- U.S. Food and Drug Administration (FDA). (2020). Pemigatinib approval letter.
- MarketWatch. (2023). Oncology drug sales forecasts.
- IQVIA. (2023). Global oncology market insights.
- ClinicalTrials.gov. (2023). Current trials involving FGFR inhibitors.
